Premium
Bone marrow or adipose tissue mesenchymal stem cells: Comparison of the therapeutic potentials in mice model of acute liver failure
Author(s) -
Zare Hossein,
Jamshidi Shahram,
Dehghan Mohammad M.,
Saheli Mona,
Piryaei Abbas
Publication year - 2018
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.26772
Subject(s) - mesenchymal stem cell , adipose tissue , bone marrow , medicine , stem cell , transplantation , histopathology , stem cell therapy , carbon tetrachloride , pathology , biology , chemistry , genetics , organic chemistry
Acute liver failure (ALF) is a lethal disease with limited life‐saving therapy. Because lack of whole organ donors for liver transplantation, a substitute treatment strategy is needed for these patients. Preclinical and clinical findings have proved that treatment with mesenchymal stem cells (MSCs) is beneficial for recovery from ALF. In this approach, however, the appropriate sources of these cells are unclear. In the present study, we investigated and compared the therapeutic potentials of bone marrow‐mesenchymal stem cells (BM‐MSC) with those of adipose tissue (AT‐MSC) in carbon tetrachloride (CCL4)‐induced acute liver failure in mice. Murine BM‐ and AT‐MSCs obtained from normal mice were cultured and labelled. The cells were transplanted to CCL4‐induced ALF mice models intravenously. After cell transplantation, blood samples and liver tissues were collected daily for 72 h to analyze liver enzymes and liver histopathology, respectively. We found that survival rate of AT‐MSC transplanted (AT‐TR) mice was significantly higher than that of control (ALF) group. Liver histopathology was superior in the AT‐TR mice, but not significantly, compared to that in BM‐MSC transplanted (BM‐TR) ones. Furthermore, in the AT‐TR mice the level of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), in some time points were significantly less than those of BM‐TR. Taken together, these data suggest that in comparison to BM‐MSC, AT‐MSCs is an appropriate choice for cell therapy in the case of acute liver failure.